On June 11, 2026, the MHRA approved the UK's first oral GLP-1 tablet, a daily semaglutide pill for weight loss and weight management, signed off by the agency's Julian Beach. Eligibility covers adults with obesity (BMI 30 and above) or overweight (BMI 27 to 30) with at least one weight-related condition, with the daily dose escalating from 1.5mg up to 25mg at minimum one-month intervals. Patients already on the weekly 2.4mg injection can switch directly to the 25mg tablet.

For an aesthetic clinic, this is upstream of you, but it points at your funnel. Taking the needle out of GLP-1 access tends to widen the user base, and a wider weight-loss population feeds the same downstream demand clinics are already absorbing: facial volume loss, skin laxity, and body-contouring interest after the weight comes off. The tablet was not commercially available at the announcement, so there is no immediate rush.

Worth noting for UK-facing practices and anyone tracking how big the post-weight-loss aesthetic pipeline gets over the next year.

Source: GOV.UK (MHRA) — https://www.gov.uk/government/news/first-glp-1-tablet-for-weight-loss-approved-in-the-uk